Company intelligence / Profile preview

AlaMab Therapeutics

Princeton, New Jersey, United Statesalamab.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ALMB-0166 is in Phase 2 clinical trials for acute spinal cord injury, while ALMB-0168 is in Phase 1 for osteosarcoma. As of 2024, both drugs have received approval for first-in-human clinical trials in Australia. ALMB-0166 has been granted Orphan-Drug Designation by the U.S. FDA for acute spinal cord injury, and ALMB-0168 has received Rare Pediatric Disease Designation from the FDA.

Therapeutic areas: OncologyNeurology
Modalities: Monoclonal antibodiesAntibody therapeuticsFirst-in-class antibody drugs
Industry: Biotech

Drug pipeline

4 assets

ALMB-0168

3 more assets in the full pipeline.

Request access →

Partnerships

University of Texas

Beyond the preview

Go deeper on AlaMab Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlaMab Therapeutics.

Explore the full profile